Article
Multidisciplinary Sciences
Weijie Cao, Xiaoning Li, Ran Zhang, Zhilei Bian, Suping Zhang, Li Li, Haizhou Xing, Changfeng Liu, Xinsheng Xie, Zhongxing Jiang, Xiaosheng Fang, Dingming Wan, Jifeng Yu
Summary: In this study, we aimed to validate and prove the effectiveness of AML-DRG and AML-HCT-CR models in predicting post-transplant survival in patients with acute myeloid leukemia (AML) receiving allogeneic hematopoietic stem cell transplantation (AHCT). Our results showed that these models significantly predicted the cumulative incidence of relapse and AML-DRG model demonstrated better stratification of AML patients into different risk groups compared to the AML-HCT-CR model. Multivariate analysis confirmed the independent prognostic impact of these models on post-transplant overall survival.
SCIENTIFIC REPORTS
(2022)
Review
Oncology
Rahul K. K. Nayak, Yi-Bin Chen
Summary: Allogeneic hematopoietic cell transplant is a central treatment for acute myeloid leukemia in first complete remission, but disease relapse remains a concern. Ongoing investigations are exploring maintenance therapies including targeted agents, hypomethylating agents, immunomodulatory therapies, and cellular therapies.
FRONTIERS IN ONCOLOGY
(2022)
Review
Immunology
Guancui Yang, Xiang Wang, Shiqin Huang, Ruihao Huang, Jin Wei, Xiaoqi Wang, Xi Zhang
Summary: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for myeloid malignancies, but relapse and graft-versus-host disease (GvHD) still impact patient survival. Epigenetic agents, such as hypomethylating agents (HMAs), have been explored to reduce relapse risk and prevent GvHD, and combining epigenetic therapy with HSCT may optimize the transplantation process and prevent treatment failure.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Yimei Feng, Ting Chen, Yun Zhang, Han Yao, Ping Wang, Lu Wang, Kaniel Cassady, Zhongmin Zou, Yuqing Liu, Lu Zhao, Lei Gao, Xi Zhang, Peiyan Kong
Summary: This study examines the efficacy and tolerability of maintenance therapy with azacytidine (AZA) plus low-dose lenalidomide (LEN) to prevent relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for acute myeloid leukemia (AML) patients. The results show that this treatment regimen plays a significant role in preventing relapse without significantly increasing the risk of complications post-transplantation.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Takashi Tanaka, Yoshihiro Inamoto, Ayumu Ito, Mizuki Watanabe, Wataru Takeda, Jun Aoki, Sung-Won Kim, Takahiro Fukuda
Summary: This study retrospectively evaluated the efficacy and safety of lenalidomide in patients with recurrent adult T-cell leukemia/lymphoma after allogeneic hematopoietic cell transplantation. The results showed that lenalidomide may improve survival and administering lenalidomide before mogamulizumab treatment may enhance efficacy.
HEMATOLOGICAL ONCOLOGY
(2023)
Review
Oncology
Iman Abou Dalle, Ali Atoui, Ali Bazarbachi
Summary: Relapsed acute myeloid leukemia (AML) following allogeneic hematopoietic cell transplantation (allo-HCT) is a challenging event, and the current treatment landscape is still facing difficulties. Recent research has allowed the development of new strategies that can improve remission rates and prolong survival.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Katrin Teich, Michael Stadler, Razif Gabdoulline, Jyoti Kandarp, Clara Wienecke, Bennet Heida, Piroska Klement, Konstantin Buttner, Letizia Venturini, Martin Wichmann, Wolfram Puppe, Christian Schultze-Florey, Christian Koenecke, Gernot Beutel, Matthias Eder, Arnold Ganser, Michael Heuser, Felicitas Thol
Summary: Donor lymphocyte infusions (DLIs) can be used to prevent or treat relapse in acute myeloid leukemia (AML) patients after allogeneic hematopoietic cell transplantation (alloHCT). Measurable residual disease (MRD) is a valuable biomarker for predicting the response and outcome of DLI treatment. This retrospective study showed that MRD status before and after DLI treatment is prognostic for event-free survival, overall survival, cumulative incidence of relapse, and relapse-free survival.
Article
Hematology
Ting-Ting Yang, Xiao-Lu Song, Yan-Min Zhao, Bao-Dong Ye, Yi Luo, Hao-Wen Xiao, Yi Chen, Hua-Rui Fu, Jian Yu, Li-Zhen Liu, Xiao-Yu Lai, Yi-Shan Ye, Jian-Ping Lan, He Huang, Ji-Min Shi
Summary: The use of VEN-based therapy followed by allo-HSCT is feasible in AML patients and does not increase the risk of transplant-related mortality and toxicity.
ANNALS OF HEMATOLOGY
(2022)
Article
Biophysics
Evgenii Shumilov, Inna Shakhanova, Johanna Flach, Nicole Schmidt, Susanne Buerki, Myriam Legros, Marie-Noelle Kronig, Yishai Ofran, Sabine Gerull, Michael Medinger, Behrouz Mansouri Taleghani, Jakob Passweg, Joerg Halter, Ulrike Bacher, Thomas Pabst
Summary: Our study found that around 79% of AML patients can undergo salvage therapy following relapse after autologous HCT, with approximately 47% proceeding to receive allogeneic HCT. Patients who received allogeneic HCT had estimated 3-year leukemia-free and overall survival rates of around 33% and 43%.
BONE MARROW TRANSPLANTATION
(2022)
Article
Immunology
Yingying Huo, Linjie Wu, Aiming Pang, Qing Li, Fang Hong, Caiying Zhu, Zining Yang, Weiqian Dai, Yawei Zheng, Qianqian Meng, Jiali Sun, Shihui Ma, Linping Hu, Ping Zhu, Fang Dong, Xin Gao, Erlie Jiang, Sha Hao, Tao Cheng
Summary: Hematopoietic stem cell transplantation is an effective regenerative therapy for various diseases, but our understanding of the reconstitution process is limited. This study reveals the dynamics of transplanted hematopoietic stem and progenitor cells (HSPCs) in humans. Transcriptomic analysis shows that immunoregulatory neutrophil progenitors expressing high levels of the S100A gene family are enriched in peripheral blood stem cells. Patients with acute graft-versus-host disease (aGVHD) have fewer S100Ahigh immunoregulatory neutrophil progenitors, suggesting a potential criterion for identifying high-risk patients.
SCIENCE IMMUNOLOGY
(2023)
Review
Clinical Neurology
Zhuo Wang, Munan Zhao, Sujun Gao
Summary: The incidence of epileptic seizures after allogeneic hematopoietic stem cell transplantation has raised concerns among clinicians for its impact on patient survival and quality of life. This review aims to elucidate the incidence, etiologies, mechanisms, clinical manifestations, therapeutic schedule, and prognosis of post-transplantation seizures to improve doctors' understanding and management of this complication for better patient outcomes.
FRONTIERS IN NEUROLOGY
(2021)
Article
Gastroenterology & Hepatology
Yosuke Okada, Hideki Nakasone, Yuhei Nakamura, Masakatsu Kawamura, Shunto Kawamura, Junko Takeshita, Nozomu Yoshino, Yukiko Misaki, Kazuki Yoshimura, Shimpei Matsumi, Ayumi Gomyo, Aki Tanihara, Masaharu Tamaki, Machiko Kusuda, Kazuaki Kameda, Shun-Ichi Kimura, Shinichi Kako, Noriko Oyama-Manabe, Yoshinobu Kanda
Summary: Pancreatic atrophy is associated with chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. The recovery of pancreatic thickness plays a crucial role in body weight recovery, but pancreatic atrophy may have a negative impact on prognosis.
JOURNAL OF GASTROENTEROLOGY
(2022)
Review
Immunology
Linlu Tian, Besim Ogretmen, Brian Y. Chung, Xue-Zhong Yu
Summary: Allogeneic hematopoietic cell transplantation is an effective immunotherapy against hematopoietic malignancies, but GVHD and tumor relapse are major concerns. Sphingolipid metabolism plays a crucial role in immune responses, highlighting the need to explore therapeutic strategies targeting sphingolipid metabolism.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biophysics
Shuhui Jiang, Yi Fan, Yanglan Fang, Chang Hou, Jia Chen, Jiannong Cen, Huiying Qiu, Suning Chen, Yang Xu, Depei Wu
Summary: The quantification of the EVI1 gene in MLL-r AML patients undergoing allo-HSCT showed that high EVI1 expression was associated with poorer overall survival, disease-free survival, and higher relapse rates. EVI1 could serve as an important marker for early prediction of relapse in these patients.
BONE MARROW TRANSPLANTATION
(2021)
Article
Medicine, General & Internal
Leyre Bento, Mariana Canaro, Jose Maria Bastida, Antonia Sampol
Summary: Thrombopoietin receptor agonists have shown good tolerability and efficacy as a new strategy for treating post-transplant thrombocytopenia. Prospective trials are needed to confirm these results.
JOURNAL OF CLINICAL MEDICINE
(2022)